Molecular Excipient

121.0 -2.7 2 3 68.0 2 0.67
Present in 89 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
CPA1 Carboxypeptidase A1 Enzyme / Protease

Clinical Trials

This compound has been an intervention in the following clincial trials (per
Code Date Title Phase Status
NCT02348775 2014-11-01 Glutathione and Function in HIV Patients Phase 1 Recruiting
NCT02348762 2014-11-01 Energetics and Function in Older Humans Phase 1 Recruiting
NCT02252341 2014-09-01 Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder Phase 4 Enrolling By Invitation
NCT02206152 2014-07-01 A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes Phase 1/Phase 2 Not Yet Recruiting
NCT02117700 2014-05-01 Fatty Liver Disease in Obese Children Phase 2 Not Yet Recruiting
NCT02050139 2014-02-01 L-Cysteine in Peritoneal Dialysis Phase 2 Recruiting
NCT02124941 2014-02-01 Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 13C-MRS Phase 1 Recruiting
NCT01840345 2014-01-01 The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain Phase 2 Recruiting
NCT01820195 2013-03-01 N-Acetyl Cystein and Contrast Nephropathy Phase 3 Recruiting
NCT01841411 2013-03-01 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Phase 4 Recruiting
NCT01878669 2013-01-01 Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention Phase 3 Recruiting
NCT01797575 2013-01-01 N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder Phase 2 Recruiting
NCT01063348 2012-09-01 N-Acetyl Cysteine in Pathologic Skin Picking Phase 2 Recruiting
NCT02239107 2012-01-01 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Phase 4 Completed
NCT01339858 2011-05-01 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Phase 4 Recruiting
NCT01403506 2011-04-01 Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL) Phase 3 Recruiting
NCT01614431 2011-03-01 N Acetyl Cysteine for Cystinosis Patients Phase 4 Completed
NCT01322009 2011-03-01 Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury Phase 1/Phase 2 Recruiting
NCT01251315 2010-12-01 The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels Phase 1 Completed
NCT01241513 2010-11-01 Induced Changes in Ventilatory Responsiveness and Altitude Exposure Phase 4 Completed
NCT01355198 2010-08-01 Role of HIV on Glutathione Synthesis and Oxidative Stress Phase 1 Completed
NCT01099332 2009-11-01 Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease Phase 1/Phase 2 Active, Not Recruiting
NCT00967005 2009-09-01 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Phase 2 Active, Not Recruiting
NCT00975689 2009-08-01 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Phase 1/Phase 2 Completed
NCT00866866 2009-03-01 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Phase 4 Recruiting
NCT00829205 2009-01-01 Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment Phase 1/Phase 2 Withdrawn
NCT00676195 2008-06-01 An Open-Label Study of N-Acetyl Cysteine in Children With Autism Phase 2 Completed
NCT00627705 2008-02-01 A Study of N-Acetyl Cysteine in Children With Autism Phase 2 Completed
NCT00489372 2007-07-01 Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients Phase 1 Completed
NCT00254176 2006-09-01 Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3 Active, Not Recruiting
NCT00354770 2006-07-01 N-Acetyl Cysteine in Trichotillomania Phase 2 Completed
NCT00332605 2006-06-01 N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence Phase 2 Completed
NCT00273702 2006-01-01 An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling Phase 1 Completed
NCT00863785 2004-04-01 Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone Phase 3 Completed
NCT01506765 2003-08-01 Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia Phase 1 Completed
NCT00004940 1996-05-01 Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria Phase 3 Completed

(Browse) Purchasable Analogs in ZINC

Regulatory Status of Cysteine

Gras - Generally recognized as safe.


Route Formulation Per Unit Dose
Im - Sc Injection, Sustained Action 0.1%
Intravenous Powder, For Injection Solution, Lyophilized 2.6%
Iv(infusion) Solution, Injection 0.02%

More Information

Usage Over Time